U.S. Contraceptive Market Size, Share & Trends Report

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product (Pills, Condoms, Diaphragms, Sponge, Vaginal Ring, Subdermal Implants, IUD, Patch, Injectable), And Segment Forecasts, 2020 - 2027

  • Published Date: Feb, 2020
  • Base Year for Estimate: 2019
  • Report ID: GVR-2-68038-702-5
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2018
  • Number of Pages: 80

Industry Insights

The U.S. contraceptive market size was valued at around USD 7 billion in 2019 and is projected to expand at a CAGR of around 4.2% over the forecast period. Increasing awareness regarding the importance of sexual and reproductive health among women in the age group of 15 to 49 years is expected to boost the use of various birth control methods in the country. According to the Centers for Diseases Control and Prevention (CDC), nearly two-thirds of sexually active women use one of the methods of contraception. Modern contraceptive methods such as condoms, pills, and implants are preferred by young women-from 15 to 29 years.

In 2018, 43 million women in U.S. were at the risk of unintended pregnancy. According to the CDC, 19.5 million women still lack access to healthcare centers offering a full range of contraceptive methods. Women living in underdeveloped and developing counties have limited access to modern birth control which leads to unwanted pregnancy or abortion. Thus, increasing demand for contraceptives to maintain a small family or to avoid additional healthcare costs is likely to aid market growth.

U.S. contraceptive Market

According to the Patient Protection and Affordable Care Act, all contraceptive methods authorized by the Food and Drug Administration (FDA) must be covered by private insurance. The federal and state governments also provide reimbursements for family planning services and supplies to help women. The Center for Medicaid and CHIP Services (CMCS) established a Maternal and Infant Health Initiative for the Medicaid and Children’s Health Insurance Program (CHIP) to promote the use of effective methods of contraception. Such government initiatives to improve family planning and reproductive health has significantly increased awareness and use of contraceptive in U.S.

Married and cohabiting women are at high risk of unwanted pregnancy and prefer non-permanent birth control methods, such as hormonal contraceptives, i.e., pills, patches, implants, and vaginal rings. Availability of new and advanced more modern contraceptive methods is anticipated to increase the adoption of contraceptives.

Product Insights

On the basis of products, the U.S. contraceptive market is segmented into pills, condoms, diaphragms, sponge, vaginal ring, subdermal implants, intrauterine devices (IUDs), patch, and injectable. In 2019, pills was the most common and popular method due to convenience of use. However, Long-Acting Reversible Contraceptives (LARCs) such as subdermal implants are projected to witness the fastest growth during the forecast period due to more than 99.0% effectiveness, cost-efficiency, and quick return of natural fertility after removal.

Condom use has significantly increased in adolescents due to easy availability and convenience. Furthermore, effective protection from sexually transmitted infections and demand from the young population to enhance their sexual experience is expected to aid the product demand. The condom market in U.S. is dominated by a few leading players including Church & Dwight (Trojan), Reckitt Benckiser (Durex), and Lifestyles. The availability of different variants under the brands with high-quality standards, cost-effectiveness, and easy access from supermarkets, drug stores, and e-commerce platforms are expected to help sustain their market position.

IUD also accounted for a significant market share in 2019 and is expected to witness lucrative growth over the forecast period. This can be attributed to long-term reversible protection from pregnancy, availability of nonhormonal products and the presence of sufficient options to women are other contributing factors for the growth of the segment. ParaGuard, Mirena, and Liletta are the IUDs available in the U.S. market.

U.S. contraceptive Market

Transdermal contraceptive patch is a simple, safe, and affordable method to prevent pregnancy. The patch continuously delivers hormones and its effect lasts for a week. When used correctly, the patch is more than 99.0% effective.

Vaginal rings are polymeric devices designed to allow controlled release of drugs via intravaginal administration over an extended time to prevent pregnancy. It is a self-administered method used once a month. The ring is a simple, convenient, and safe method to prevent pregnancy. Vaginal ring also helps protect against infection of ovaries, prevent development of acne, and prevent heavy/irregular periods, bone thinning, premenstrual symptoms, and menstrual cramps. NuvaRing-a vaginal contraceptive ring-is manufactured and marketed by Merck (MSD). The product was under patent protection in U.S until April 2018.

U.S. Contraceptive Market Share Insights

The market is highly competitive in nature. Some of the key industry contributors are Merck & Co. Inc.; Bayer AG; Allergan; Afaxys, Inc.; Mayer Laboratories, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; TherapeuticsMD Inc.; Reckitt Benckiser Plc.; Pfizer, Inc.; Cooper Surgical; Church & Dwight Co., Inc.; and Mithra Pharmaceuticals. Companies are undertaking strategic initiatives such as increasing investment in R&D of innovative products to gain a competitive edge from generic products available in the market.

High investments by prominent companies for the commercialization of effective and long-term reversible contraceptives have increased the awareness levels about these products. For instance, the success rate of subdermal implants is more than 99% and it is easy to use. In August 2018, the FDA approved a new vaginal ring, Annovera, for pregnancy prevention.

Report Scope

Attribute

Details

Base year for estimation

2019

Actual estimates/Historic data

2016 - 2018

Forecast period

2020 - 2027

Market representation

Revenue in USD Million & CAGR from 2020 to 2027

Country scope

U.S.

Report coverage

Revenue forecast, company share, competitive landscape, growth factors & trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2016 to 2027. For this study, Grand View Research has segmented the U.S. contraceptive market based on product:

  • Product Outlook (Revenue, USD Million; 2016 - 2027)

    • Pills

    • Condoms

      • Male Condoms

      • Female Condoms

    • Diaphragms

    • Sponge

    • Vaginal Ring

    • Subdermal Implants

    • IUD

      • Hormonal IUD

      • Nonhormonal IUD

    • Patch

    • Injectable

Key questions answered by the report
Request for Customization

Pricing & Purchase Options

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified